Shots:

• Following the AstraZeneca’s discussion with the Japanese government to introduce COVID-19 vaccine in Japan- Daiichi Sankyo has advanced its conversation with AstraZeneca to formulate the vaccine- including vial filling- packaging- and storage
• Daiichi Sankyo plans to receive Oxford's undiluted vaccine- which it will finish at its own facilities. The collaboration allows AstraZeneca to reach its goal of producing 2B doses/year
• Additionally- Daiichi Sankyo will continue its ongoing research and development of an inhaled formulation of anticoagulant Nafamostata & will advance its mRNA vaccine candidate- co-developed with the University of Tokyo

Click here to read full press release/ article 

Ref: Daiichi Sankyo | Image: Pharmashots